Details

Autor(en) / Beteiligte

• Stüber, Tanja
• Novopashenny, Igor
• Diessner, Joachim
• Bartmann, Catharina
• Stein, Roland
• Krockenberger, Mathias
• Häusler, Sebastian
• Janni, Wolfgang
• Kreienberg, Rolf
• Blettner, Maria
• Wöckel, Achim
• Wischnewsky, Manfred

Titel

Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy?

Ist Teil von

• Oncology, 2017-01, Vol.92 (6), p.317-324

Ort / Verlag

Basel, Switzerland: S. Karger AG

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Objective: To identify subgroups of patients with pT1 pN0 breast cancer (BC) who might not profit from adjuvant systemic therapy (AST). Methods: Data of 3,774 pT1 pN0 BC patients from 17 certified BC centres within the BRENDA study group were collected between 1992 and 2008 and retrospectively analysed. Uni- and multivariate analyses were performed using Kaplan-Meier methods and Cox regression models. Results: 279 (7.4%) of the pT1 pN0 BC patients were T1a, 944 (25.0%) were T1b and 2,551 (67.6%) were T1c. There was no significant difference (p > 0.1) in recurrence-free survival (RFS)/overall survival (OAS) between patients with pT1a, pT1b, and T1c. Patients receiving any type of AST had a better outcome compared to women without AST after adjusting for age, tumour size, and intrinsic subtypes (RFS: p < 0.001; OAS: p < 0.001). AST was the most important prognostic parameter for RFS followed by intrinsic subtypes and age. Conclusion: Patients with pT1 pN0 BC profit from AST independently of molecular subtypes, tumour size, age or comorbidity, with 5-year RFS of more than 95%. The correct definition of subgroups of patients who do not need AST is still an open question.